Welcome to LookChem.com Sign In|Join Free
  • or
[3-(2,5-dioxo-1-phenyl-imidazolidin-4-yl)-propyl]-guanidine is a complex organic compound with the molecular formula C12H15N5O2. It is characterized by a guanidine group attached to a 3-(2,5-dioxo-1-phenyl-imidazolidin-4-yl)-propyl chain. [3-(2,5-dioxo-1-phenyl-imidazolidin-4-yl)-propyl]-guanidine is known for its potential applications in pharmaceuticals, particularly as a precursor in the synthesis of certain drugs. Its structure features a phenyl ring, an imidazolidine ring, and a guanidine functional group, which contribute to its reactivity and biological activity. The compound's properties, such as solubility and stability, can vary depending on the conditions and its intended use.

7684-08-4

Post Buying Request

7684-08-4 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

7684-08-4 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 7684-08-4 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 7,6,8 and 4 respectively; the second part has 2 digits, 0 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 7684-08:
(6*7)+(5*6)+(4*8)+(3*4)+(2*0)+(1*8)=124
124 % 10 = 4
So 7684-08-4 is a valid CAS Registry Number.

7684-08-4Downstream Products

7684-08-4Relevant academic research and scientific papers

Identification of Multiple Structurally Distinct, Nonpeptidic Small Molecule Inhibitors of Protein Arginine Deiminase 3 Using a Substrate-Based Fragment Method

Jamali, Haya,Khan, Hasan A.,Stringer, Joseph R.,Chowdhury, Somenath,Ellman, Jonathan A.

, p. 3616 - 3621 (2015)

The protein arginine deiminases (PADs) are a family of enzymes that catalyze the post-translational hydrolytic deimination of arginine residues. Four different enzymologically active PAD subtypes have been characterized and exhibit tissue-specific expression and association with a number of different diseases. In this Article we describe the development of an approach for the reliable discovery of low molecular weight, nonpeptidic fragment substrates of the PADs that then can be optimized and converted to mechanism-based irreversible PAD inhibitors. The approach is demonstrated by the development of potent and selective inhibitors of PAD3, a PAD subtype implicated in the neurodegenerative response to spinal cord injury. Multiple structurally distinct inhibitors were identified with the most potent inhibitors having >10,000 min-1 M-1 kinact/KI values and ≥10-fold selectivity for PAD3 over PADs 1, 2, and 4. (Figure Presented).

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 7684-08-4